Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients
Personalized gene therapy targeting SCN2A mutations has shown early clinical success, enabling mobility in patients with rare developmental epilepsy.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
New clinical reports detail the use of bespoke antisense oligonucleotides (ASOs) to treat SCN2A-related developmental epileptic encephalopathy. This therapeutic approach focuses on targeting allele-specific faulty mRNA within patients affected by these mutations.
Coverage from outlets including Nature, Technology Networks, and KPBS highlights the progress of two pediatric patients. These reports note both the functional improvements observed, such as independent walking, and the reported safety and tolerability profiles of the personalized treatment.
Observers are looking toward further developments in individualized genetic medicine. Future updates will likely monitor the long-term efficacy of these bespoke ASO treatments in additional patients.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. Updated 13m ago.
Quick answers
What is the primary condition being treated?
The treatments target SCN2A-related developmental epileptic encephalopathy (DEE), a rare genetic disorder.
How does the therapy work?
According to coverage, the therapy uses personalized antisense oligonucleotides to target allele-specific faulty mRNA in patients.
What outcomes have been observed?
Reported outcomes include improved safety and tolerability profiles, as well as functional gains such as independent mobility in pediatric patients.
Coverage (8)
- Teen With SCN2A-Related DEE Walked Independently for First Time After Gene Therapy Technology Networks · 1d ago
- Teen with ultra-rare genetic disorder walks again after receiving personalized gene therapy De Último Minuto · 1d ago
- A San Diego teen's first steps offer hope for those with rare diseases KPBS · 1d ago
- Impressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature Medicine Yahoo Finance Singapore · 1d ago
- Two Children With a Rare Epilepsy Mutation Show Improvement After Personalized Genetic Treatment Discover Magazine · 1d ago
- Individualized gene therapy shows early promise for SCN2A-related epileptic encephalopathy Contemporary Pediatrics · 1d ago
- Individualized antisense oligonucleotides for SCN2A- related developmental epileptic encephalopathy Nature · 1d ago
- Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients Hackaday · 1d ago
Topics
Related trends
Precise DNA base editing using AlphaFold3-based contact modelling
Researchers are utilizing AlphaFold3-based contact modelling to redesign gene-editing proteins, aiming to improve safety in CRISPR applications.
Science thought the human lifespan was 122 years. A new model says we could live decades longer.
New scientific modeling challenges the long-standing 122-year human lifespan limit, suggesting potential for much longer life.
Science thought the human lifespan was 122 years. A new model says we could live decades longer.
New research suggests the human lifespan could reach 156 years, challenging the long-standing belief that the biological limit is 122 years.
$160 million ‘moonshot’ backs Boston effort to revolutionize rare disease treatment
A new $160 million non-profit initiative in Boston aims to accelerate the development of genetic therapies for rare and ultra-rare diseases.
Huge study finds first genetic clues for borderline personality disorder
Researchers have identified the first genetic risk markers linked to borderline personality disorder in a large-scale genome-wide association study.
Mapping in-cell protein contact sites reveals hijacking of paraspeckles during influenza A virus infection
Researchers have developed a molecular map detailing how the influenza A virus infiltrates and repurposes human cell machinery to replicate.